Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 16NETWORK 2NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 63Head & Neck 53Thoracic 40Gastrointestinal 40CNS 22Genitourinary 19Sarcoma 11Lymphoid 11Other solid neoplasm 6Dermatologic 3Breast 3Plasma cell 2Other neoplasm 2Endocrine 2Classical hematology 2Tumor-Agnostic 1Other 1

Conditions

Multiple Myeloma 2

Interventions

Dexamethasone 48Bortezomib 22Lenalidomide 20Cyclophosphamide 20daratumumab 18Calcium Dobesilate 15Melphalan 13Thalidomide 12carfilzomib 9pomalidomide 7Prednisone 7dexamethasone acetate 6dexamethasone 21-phosphate 6auricularum 6Peripheral Blood Stem Cell Transplantation 6Doxorubicin 6isatuximab 5Filgrastim 5Vincristine 4Interferon-alpha 3Etoposide 3selinexor 2sargramostim 2ixazomib 2elotuzumab 2cobimetinib 2belantamab mafodotin 2Steroids 2Stem Cell Transplantation 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Cisplatin × Plasma cell × Clear all
NCT00005834 2015-03-06

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

SWOG Cancer Research Network

Phase 3 Terminated
19 enrolled
Plasma cell

Multiple Myeloma

NCT01055301 2015-03-06

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

SWOG Cancer Research Network

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡